{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:11:14Z","timestamp":1792163474613,"version":"4.4.0"},"reference-count":69,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Paroxetine, also known by the trade names Aropax, Paxil, Pexeva, Seroxat, Sereupin and Brisdelle, was first marketed in the U.S. in 1992. Effective for major depression and various anxiety disorders, it quickly gained a sizable share of the antidepressant prescription market. By the late 1990s, paroxetine frequently was being associated with serious drug interactions and medication side effects. Most significantly, in a major Canadian epidemiological study examining the relationship between antidepressants and diseases, paroxetine was associated with a 620 percent increase in the rate of breast cancer in women who had taken it over a four-year period. Though re-analyses of this investigation discounted the magnitude of these findings, other studies have associated paroxetine with numerous side effects and adverse events not reported in clinical trials. Among these are effects on male fertility, birth defects, gestational hypertension, prolonged QT interval in infants, hyperprolactinemia, cognitive impairment in the elderly, autism, sexual side effects, weight gain, and suicidality, aggression, and akathisia in children and adolescents. Paroxetine has the highest inhibitory constant for the P450 2D6 isoenzyme of all antidepressants (Ki = 0.065\u20134.65 micromoles). This high affinity explains its high inhibitory interaction profile with substrates for 2D6. Paroxetine\u2019s potent 2D6 inhibition also implies that significant inhibition of the metabolism of 2D6 carcinogen substrates occurs which implies an increased probability of oncogenesis. Through 2D6 inhibition, tamoxifen metabolism is inhibited, which has been found to increase the risk of dying from breast cancer over a five-year period in women on both medications. Paroxetine also is a potent inhibitor of 3A4 with multiple 3A4 substrate interactions. Paroxetine has the highest known affinity for the serotonin transporter (0.13 nanomoles) of any currently used antidepressant. These characteristics and their potential negative consequences along with other adverse effects are considered and weighed against paroxetine\u2019s efficacious antidepressant and anxiolytic effects.<\/jats:p>","DOI":"10.64719\/pb.4345","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"77-104","source":"Crossref","is-referenced-by-count":26,"title":["Paroxetine\u2014The Antidepressant from Hell? Probably Not, But Caution Required"],"prefix":"10.64719","volume":"46","author":[{"given":"Robert M.","family":"Nevels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Gontkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryman E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Chong WW, Aslani P, Chen TF. Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. Int J Clin Pract. 2011;65:954\u2013975.","DOI":"10.1111\/j.1742-1241.2011.02746.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Zimmerman M, Galione JN, Attiullah N, Friedman M, Toba C, Boerescu DA, Ragheb M. Underrecognition of clinically significant side effects in depressed outpatients. J Clin Psychiatry. 71(4):484\u2013490.","DOI":"10.4088\/JCP.08m04978blu"},{"key":"ref3","unstructured":"Preston J, O\u2019Neal J, Talaga M. Handbook of Clinical Psychopharmacology for Therapists. 6th. Oakland, CA: New Harbinger; 2010."},{"key":"ref4","unstructured":"Stahl SM. Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd. Cambridge, United Kingdom: Cambridge University Press; 2008."},{"key":"ref5","unstructured":"Stahl SM. Essential Psychopharmacology: the Prescriber\u2019s Guide. Cambridge, United Kingdom: Cambridge University Press; 2005."},{"key":"ref6","unstructured":"Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CLF et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 1992;52:3796\u20133800."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Iishi H, Tatsuta M, Miyako B, Taniguchi H. Enhancement by the tricyclic antidepressant, desipramine, of experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis. 1993;14(9):1837\u20131840.","DOI":"10.1093\/carcin\/14.9.1837"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Kelly JP, Rosenberg L, Palmer JR, Sowmya R, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol. 1999;150(8):861\u2013868.","DOI":"10.1093\/oxfordjournals.aje.a010091"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer. Am J Epidemiol. 2000;151(10):951\u2013957.","DOI":"10.1093\/oxfordjournals.aje.a010138"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Schatzberg AF, Nemeroff CB. Essentials of Clinical Psychopharmacology. 2nd. Arlington, VA: American Psychiatric Publishing; 2006.","DOI":"10.1176\/appi.books.9781585623167"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin RL, Avorn J. Antidepressant use and the risk of breast cancer. J Clin Epidemiol. 2001;54:728\u2013734.","DOI":"10.1016\/S0895-4356(00)00354-1"},{"key":"ref12","unstructured":"Love S. Antidepressants and breast cancer risk. Women\u2019s Health Network. 2009;3(6):23\u201328."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sharpe CR, Collet J-P, Belzile E, Hanley JA, Boivin J-F. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer. 2002;86(1):92\u201397.","DOI":"10.1038\/sj.bjc.6600013"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS. Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer. 2006;94(7):1071\u20131078.","DOI":"10.1038\/sj.bjc.6603017"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bahl S, Cotterchio M, Kreiger N. Use of antidepressant medication and the possible association with breast cancer risk. Psychother Psychosom. 2003;72(4):185\u2013194.","DOI":"10.1159\/000070782"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Moorman PG, Grubber JM, Millikan RC, Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiol. 2003;14(3):307\u2013314.","DOI":"10.1097\/01.EDE.0000050695.99660.D1"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, Huybrechts KF. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers\u2019 financial associations with industry. PLoS ONE. 2011;6(4):e18210. doi: 10.1371\/journal.pone.0018210.","DOI":"10.1371\/journal.pone.0018210"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol. 2003;32(6):961\u2013966.","DOI":"10.1093\/ije\/dyg155"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Res Treat. 2006;95(2):131\u2013140.","DOI":"10.1007\/s10549-005-9056-0"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Coogan PF, Strom BL, Rosenberg L. SSRI use and breast cancer risk by hormone receptor status. Breast Cancer Res Treat. 2008;109(3):527\u2013531.","DOI":"10.1007\/s10549-007-9664-y"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340(c693)","DOI":"10.1136\/bmj.c693"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Chen Z, Zhou D, Hsin L-Y, Kanawa N, Wong C, Yip R, Sakamuru S, Xia M, Yuan Y-C, Witt K, Teng C. AroER Tri-Screen\u2122 is a Biologically Relevant Assay for Endocrine Disrupting Chemicals Modulating the Activity of Aromatase and\/or the Estrogen Receptor. Toxicol Sci. 2014;139(1):198\u2013209. doi: 10.1093\/toxsci\/kfu023. First published online February 4 2014.","DOI":"10.1093\/toxsci\/kfu023"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Chen Z, Zhou D, Hsin L-Y, Kanawa N, Wong C, Yip R, Sakamuru S, Xia M, Yuan Y-C, Witt K, Teng C. Cell-Based High-Throughput Screening for Aromatase Inhibitors in the Tox21 10K. LibraryToxicol Sci. 2015;147(2):446\u2013457. first published online July 3, 2015.","DOI":"10.1093\/toxsci\/kfv141"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Aubert R, Stanek E, Yao J, Teagarden JR, Subar M, Epstein RS, Skaar TC, Desta Z, Flockhart DA. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol. 2009;27:18s.","DOI":"10.1200\/jco.2009.27.18_suppl.cra508"},{"key":"ref25","unstructured":"US Food and Drug Administration. FDA Approves the First Non-hormonal Treatment for Hot Flashes Associated with Menopause. Rockville, MD: FDA News; Jun 28, 2013."},{"key":"ref26","unstructured":"Julien RM, Advokat CD, Comaty JE. A Primer of Drug Action: A Comprehensive Guide to the Actions, Uses, and Side Effects of Psychoactive Drugs. 12th. New York, NY: Worth; 2010."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, Kohane I, Roden DM, Altman RB. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther. 2011;90(1):133\u2013142.","DOI":"10.1038\/clpt.2011.83"},{"key":"ref28","unstructured":"Preskorn SH, Flockhart D. 2010 Guide to Psychiatric Drug Interactions. Prim Psychiatry. 2009;16(12):45\u201374."},{"key":"ref29","unstructured":"US Food and Drug Administration. FDA Advising of Risk of Birth Defects with Paxil. Rockville, MD: FDA News; 2005. http:\/\/69.20.19.211\/bbs\/topics\/NEWS\/2005\/NEW01270."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Diav-Citrin O, Shechtman S, Weinbaum D et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Br J Clin Pharmacol. 2008;66(5):695\u2013705.","DOI":"10.1111\/j.1365-2125.2008.03261.x"},{"key":"ref31","unstructured":"GlaxoSmithKline US Cohort Study of Paxil and Birth Defects Risk. 2012 Jan 5; Retrieved from GlaxoSmithKline website for Paxil."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Huybrechts KF, Palmsten K, Avorn J et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370:2397\u20132407.","DOI":"10.1056\/NEJMoa1312828"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Sengwee T, Mitchell AA, Louik C, Werler MC, Chambers CD, Hern\u00e1ndez-D\u00edaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry. 2009;166:320\u2013328.","DOI":"10.1176\/appi.ajp.2008.08060817"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med. 2006;354(6):579\u2013587.","DOI":"10.1056\/NEJMoa052744"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Reefhuis J, Devine O, Friedman J, Louik C, Honeim M. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ. 2015;351 doi: 10.1136\/bmj.h3190. (Published 08 July 2015)","DOI":"10.1136\/bmj.h3190"},{"key":"ref36","unstructured":"Correa A, Cragan JD, Kucik ME, Alverson CJ, Gilboa SM, Balakrishnan R, Strickland MJ, Duke CW, O\u2019Leary LA, Riehle-Colarusso T, Siffel C, Gambrell D, Thompson D, Atkinson M, Chitra J. Reporting birth defects surveillance data 1968-2003. Birth Defects Res A Clin Mol Teratol. 2007;79:65\u2013186."},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. Paroxetine in human breast milk and nursing infants. Am J Psychiatry. 2000;157:185\u2013189.","DOI":"10.1176\/appi.ajp.157.2.185"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol. 2005;25(1):59\u201373.","DOI":"10.1097\/01.jcp.0000150228.61501.e4"},{"key":"ref39","unstructured":"Hale TW, Rowe H. Medications and Mother\u2019s Milk. 16th. Hale Publishing LP; Plano, TX: 2014."},{"key":"ref40","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. Safety Announcement (December 14, 2011).The FDA is updating the public on the use of selective serotonin reuptake inhibitor (SSRI) antidepressants by women during pregnancy and the potential risk of a rare heart and lung condition known as persistent pulmonary hypertension of the newborn (PPHN) Rockville, MD: FDA News; No page numbers."},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders. Arch Gen Psychiatry. 2011;68(11):1104\u20131112. doi: 10.1001\/archgenpsychiatry.2011.73.","DOI":"10.1001\/archgenpsychiatry.2011.73"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Harrington R, Lee L-C, Crum R, Zimmerman A, Hertz-Picciotto I. Prenatal SSRI Use and Offspring with Autism Spectrum Disorder or Developmental Delay. Pediatrics. 2014;133(5):133, e1241. doi: 10.1542\/peds.20133406. originally published online April 14, 2014.","DOI":"10.1542\/peds.20133406"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Boukhris T, Sheehy O, Mottron L, B\u00e9rard A. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016;170(2):117\u2013124. doi: 10.1001\/jamapediatrics.2015.3356.","DOI":"10.1001\/jamapediatrics.2015.3356"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863\u2013867.","DOI":"10.4088\/JCP.v61n1109"},{"key":"ref45","unstructured":"Rosko T. Psychiatric medications and weight gain: a review. Bariatric Times. 2011;8(3):12\u201315."},{"key":"ref46","unstructured":"Nebes RD, Pollock BG, Mulsant BH, Butters MA, Zmuda MD, Reynolds III CF. Cognitive effects of paroxetine in older depressed patients. J Clin Psychiatry. 1999;60(suppl. 20):26\u201329."},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Cassano GB, Puca F, Scapicchio PL, Trabucchi M. Italian Study Group on Depression in Elderly Patients Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry. 2002;63(5):396\u2013402.","DOI":"10.4088\/JCP.v63n0504"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Furlan PM, Kallan MJ, Have TT, Pollock BG, Katz I, Lucki I. Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers. Amer J Geriatr Psychiatry Autumn. 2001;9(4): 429\u2013438.","DOI":"10.1097\/00019442-200111000-00012"},{"key":"ref49","unstructured":"Potentially Harmful Drugs in the Elderly: Beers List. PHARMACIST\u2019S LETTER\/PRESCRIBER\u2019S LETTER. Therapeutic Research Center; Stockton, CA: Jun, 2012. pp. 1\u201316. PL Detail-Document #280610."},{"key":"ref50","unstructured":"Nevels RM, Gontkovsky ST. Pharmacological treatment of dementia: Do medications work? In: Gontkovsky ST, editor. The Cognitive Therapeutics Method: Non-Pharmacological Approaches to Slowing the Cognitive and Emotional Decline Associated with Dementia. Home Care Press; Palo Alto: 2014. pp. 39\u201364."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Abler B, Seeringer A, Hartmann A, Gr\u00f6n G, Metzger C, Walter M, Stingl J. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology. 2011;36:1837\u20131847.","DOI":"10.1038\/npp.2011.66"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ. 2005;331 doi: 10.1136\/bmj.331.7516.529.","DOI":"10.1136\/bmj.331.7516.529"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79:1862\u20131865.","DOI":"10.1212\/WNL.0b013e318271f848"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Palmsten K, Hern\u00e1ndez-Diaz S, Huybrechts KF, Williams PL, Michels KB, Achtypes ED, Moogun H, Setoguchi S. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ. 2013;347:f4877. doi: 10.1136\/bmj.f4877. Published online 2013 Aug 21.","DOI":"10.1136\/bmj.f4877"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Bruning AH, Heller HM, Kieviet N, Bakker PC, de Groot CJ, Dolma KM, Honig A. Antidepressants during pregnancy and postpartum hemorrhage: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2015;189:38\u201347. doi: 10.1016\/j.ejogrb.2015.03.022. Epub 2015 Mar 30.","DOI":"10.1016\/j.ejogrb.2015.03.022"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Hanley GE, Smolina K, Mintzes B, Oberlander TF, Morgan SG. Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. Obstet Gynecol. 2016;127(3) doi: 10.1097\/AOG.0000000000001200.","DOI":"10.1097\/AOG.0000000000001200"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006 Sep;40(9):1618\u20131622. doi: 10.1345\/aph.1G293. Epub 2006 Aug 8.","DOI":"10.1345\/aph.1G293"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"McSwan KL, Gontkovsky ST, Splinter MY. Acute changes in mental status secondary to selective serotonin reuptake inhibitor induced hyponatremia. Rehabil Psychol. 2003;48:202\u2013206.","DOI":"10.1037\/0090-5550.48.3.202"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Nevels RM, Dehon EE, Alexander K, Gontkovsky ST. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol. 2010;18(2):184\u2013201.","DOI":"10.1037\/a0018059"},{"key":"ref60","unstructured":"Vedantam S. FDA links antidepressants, youth suicide risk. The Washington Post: 2004. Feb 3, p. A01."},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationships between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry. 2006;163(11):1898\u20131904.","DOI":"10.1176\/ajp.2006.163.11.1898"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher MD, Pincus HA, Ren L, Brent DA. Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials. JAMA. 2007;297(15):1683\u20131696. doi: 10.1001\/jama.297.15.1683.","DOI":"10.1001\/jama.297.15.1683"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Jureidini J. The black box warning: decreased prescriptions and increased youth suicide? Am J Psychiatry. 2007;164(12):1907. doi: 10.1176\/appi.ajp.2007.07091463. author reply 1908-10.","DOI":"10.1176\/appi.ajp.2007.07091463"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Le Noury J, Nardo J, Healy D, Raven M, Tufanaru C, Abi-Jaoude E. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015;351 doi: 10.1136\/bmj.h4320. (Published 16 September 2015) Cite this as: BMJ. 2015;351:h4320.","DOI":"10.1136\/bmj.h4320"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Sharma T, Guski LS, Freund N, G\u00f8tzsche P. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016;352 doi: 10.1136\/bmj.i65. (Published 27 January 2016)","DOI":"10.1136\/bmj.i65"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Ben-Sheetrit J, Aizenberg D, Csoka AB, Weizman A, Hermesh H. Post-SSRI sexual dysfunction: Clinical characterization and preliminary assessment of contributory factors and dose-response relationship. J Clin Psychopharmacol. 2015;35(3):273\u2013278. doi: 10.1097\/JCP.0000000000000300.","DOI":"10.1097\/JCP.0000000000000300"},{"key":"ref67","unstructured":"Stahl SM. Antidepressants. Cambridge, United Kingdom: Cambridge University Press; 2009."},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Ozmenler NK, Karlidere T, Bozkurt A. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2008;23(4):321\u2013326. doi: 10.1002\/hup.929.","DOI":"10.1002\/hup.929"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Tanrikut C, Feldman AS, Altemus M, Paduch DA, Schlegel PN. Adverse effect of paroxetine on sperm. Fertil Steril. 2010;94(3):1021\u20131026. Epub 2009 Jun 10.","DOI":"10.1016\/j.fertnstert.2009.04.039"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:25:55Z","timestamp":1791314755000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/paroxetine-the-antidepressant-from-hell-probably-not-but-caution-required\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4345","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}